Immuron Ltd — Investor Presentation 2013

Nov 28, 2013

ORAL IMMUNOTHERAPY USING BOVINE ANTIBODIES

==> picture [822 x 100] intentionally omitted <==

----- Start of picture text -----

Forward-looking Statement
----- End of picture text -----

Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

==> picture [822 x 100] intentionally omitted <==

----- Start of picture text -----

2013: THE ACHIEVEMENTS
----- End of picture text -----

New Shareholders  April rights issue: high networth investors who provide a lot of support

Travelan: continue commercialization

Fatty Liver / NASH

 Direct-to-wholesale model in Australia, increase revenues  Regulatory approval in Canada  Regulatory progress in licensed territories  Discussions in the US progressing  Continue preparation for Phase IIb Clinical trial  ASH trial cleared by FDA  Industry (potential partner) interest

Clostridium Difficile and  Very encouraging preventative result. Treatment studies other RD ongoing.

 A number of promising applications, including for orphan conditions

==> picture [822 x 100] intentionally omitted <==

----- Start of picture text -----

LOOKING AHEAD
What we are seeking to achieve
----- End of picture text -----

Financial Strength

 Improve balance sheet

Travelan: continue commercialization

 US Travelan transaction

 More licenses and more revenue

Fatty Liver / NASH  Commence Phase IIb Clinical trial

 Partner

Progress RD  Progress to the clinic with another product

 A number of promising applications, including for orphan conditions

We continue to nurture and benefit from strong partnerships with our research and development collaborators and with our commercial partners.

==> picture [823 x 596] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
The last 3 years
Takeda shed its License
License with Takeda
pharmacy sales force Termination
6,000
5,000
4,000
3,000
2,000
1,000
0
TRAVELAN
Jan-10 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11 Jun-11 Jul-11 Aug-11 Sep-11 Oct-11 Nov-11 Dec-11 Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13
----- End of picture text -----

==> picture [822 x 100] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
Before July 2013
----- End of picture text -----

==> picture [193 x 41] intentionally omitted <==

==> picture [200 x 68] intentionally omitted <==

==> picture [84 x 58] intentionally omitted <==

==> picture [79 x 75] intentionally omitted <==

==> picture [822 x 100] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
Now (Australia)
----- End of picture text -----

Immuron is commanding substantially higher margin

==> picture [193 x 41] intentionally omitted <==

==> picture [26 x 56] intentionally omitted <==

==> picture [278 x 63] intentionally omitted <==

==> picture [159 x 102] intentionally omitted <==

==> picture [823 x 596] intentionally omitted <==

----- Start of picture text -----

TRAVELAN
Going Forward
Approved
In Discussion
In Discussion
Various
stages of
<br>regulatory<br> process
<br>Licensed In Discussion<br>
In Revenue `
Proceeding through
regulatory process
----- End of picture text -----

==> picture [822 x 100] intentionally omitted <==

----- Start of picture text -----

IMM-124E for NASH
Mechanism of Action
----- End of picture text -----

Oral Immunotherapy: An approach to treating autoimmune, infectious and inflammatory disease through the oral delivery of antibodies

There is continually growing scientific support for Immuron’s approach Immuron has the right product at the right time

==> picture [692 x 229] intentionally omitted <==

==> picture [822 x 100] intentionally omitted <==

----- Start of picture text -----

IMM-124E for NASH
Ready to go: Phase 2B trial
----- End of picture text -----

==> picture [138 x 63] intentionally omitted <==

Based on existing technology:

• Mature manufacturing process

• High Safety profile

==> picture [159 x 77] intentionally omitted <==

IND cleared by the FDA: Immuron set to commence clinical trials

Preparations under way

Investigators identified

==> picture [102 x 89] intentionally omitted <==

IMM-124E has been independently validated: selected as only 1 of 3 products to be studied for alcoholic steatohepatitis (ASH) under a fully funded NIH TREAT study

NASH remains a very large unmet medical need of significant interest to the medical profession and the pharmaceutical industry

==> picture [822 x 100] intentionally omitted <==

----- Start of picture text -----

IMM-529 for Clostridium Difficile
----- End of picture text -----

Clostridium difficile (C.diff): a bacteria normally found in people’s intestines

• Certain circumstances C.diff can multiply and its toxin causes illness such as diarrhoea & severe inflammation of the bowel

• C. diff infection accounts for:

• considerable increases in length of hospital stays

• more than US$3.2 billion in health care costs each year in the United States

==> picture [216 x 255] intentionally omitted <==

==> picture [822 x 100] intentionally omitted <==

----- Start of picture text -----

IMM-529 for Clostridium Difficile
Very encouraging results to date
----- End of picture text -----

• IMM-529 under collaboration with Monash University

• • All data owned by Immuron

• IMM-529 demonstrated positive pre-clinical results:

==> picture [121 x 130] intentionally omitted <==

• Encouraging preventative data

• Treatment effect currently being investigated

• Proprietary vaccine given to cows being improved

==> picture [299 x 65] intentionally omitted <==

==> picture [299 x 62] intentionally omitted <==

==> picture [299 x 62] intentionally omitted <==

==> picture [299 x 65] intentionally omitted <==

==> picture [299 x 63] intentionally omitted <==

==> picture [299 x 68] intentionally omitted <==

==> picture [822 x 100] intentionally omitted <==

----- Start of picture text -----

THE OPPORTUNITY
----- End of picture text -----

Thank you

Contact Amos Meltzer – Chief Executive Officer 0437 587 680